工程抗体融合蛋白用于靶向疾病治疗。
Engineered antibody fusion proteins for targeted disease therapy.
机构信息
Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Trends Pharmacol Sci. 2021 Dec;42(12):1064-1081. doi: 10.1016/j.tips.2021.09.009. Epub 2021 Oct 25.
Since the FDA approval of the first therapeutic antibody 35 years ago, antibody-based products have gained prominence in the pharmaceutical market. Building on the early successes of monoclonal antibodies, more recent efforts have capitalized on the exquisite specificity and/or favorable pharmacokinetic properties of antibodies by developing fusion proteins that enable targeted delivery of therapeutic payloads which are otherwise ineffective when administered systemically. This review focuses on recent engineering and translational advances for therapeutics that genetically fuse antibodies to disease-relevant payloads, including cytokines, toxins, enzymes, neuroprotective agents, and soluble factor traps. With numerous antibody fusion proteins in the clinic and other innovative molecules poised to follow suit, these potent, multifunctional drug candidates promise to be a major player in the therapeutic development landscape for years to come.
自 35 年前 FDA 批准首个治疗性抗体以来，抗体类药物已在药物市场中占据重要地位。基于单克隆抗体的早期成功，最近的努力利用抗体的高度特异性和/或有利的药代动力学特性，开发了融合蛋白，从而能够靶向递送至全身性给药时无效的治疗有效载荷。本综述重点介绍了将抗体与疾病相关有效载荷（包括细胞因子、毒素、酶、神经保护剂和可溶性因子陷阱）进行基因融合的治疗方法的最新工程和转化进展。许多抗体融合蛋白已在临床应用，其他创新分子也蓄势待发，这些有效、多功能的候选药物有望在未来多年成为治疗开发领域的主要力量。
Zotero 插件